

Supplementary Table S1. Clinicopathological characteristics of gastric cancer patients according to the c-MET, RhoA and CLDN18 groups.

Variables	c-MET (–) <i>n</i> = 180 (%)	c-MET(+) <i>n</i> = 169 (%)	<i>p</i>	Low-RHOA <i>n</i> = 174 (%)	High-RHOA <i>n</i> = 169 (%)	<i>p</i>	Low-CLDN18 <i>n</i> = 173 (%)	High-CLDN18 <i>n</i> = 176 (%)	<i>p</i>
BMI (Kg/cm²)			0.844			0.455			0.101
Mean (SD)	24.2 (5.3)	24.1 (5.4)		24.3 (5.5)	23.9 (5.1)		23.6 (5.3)	24.6 (5.3)	
Hemoglobin (g/dL)			0.222			0.443			0.562
Mean (SD)	12.0 (2.3)	12.3 (2.3)		12.0 (2.3)	12.2 (2.2)		12.2 (2.2)	12.1 (2.3)	
Albumin (g/dL)			0.792			0.653			0.521
Mean (SD)	4.1 (2.4)	4.1 (0.6)		4.1 (2.5)	4.1 (0.5)		4.2 (2.5)	4.0 (0.6)	
Neutrophil lymphocyte ratio (NLR)			0.743			0.648			0.493
Mean (SD)	2.74 (3.00)	2.64 (2.58)		2.62 (2.89)	2.76 (2.76)		2.80 (3.01)	2.60 (5.56)	
Charlson–Deyo Comorbidity Index (CCI)			0.710			0.524			0.801
0–1	168 (93.3)	156 (92.3)		160 (92)	164 (93.7)		160 (92.5)	164 (93.2)	
> 1	12 (6.7)	12 (7.7)		14 (8)	11 (6.3)		13 (7.5)	12 (6.8)	
pM status			0.809			0.337			0.749
pM0	175 (97.2)	165 (97.6)		168 (96.6)	172 (98.3)		168 (97.1)	172 (97.7)	
pM1	5 (2.8)	4 (2.4)		6 (3.3)	3 (1.7)		5 (2.9)	4 (2.3)	
c-MET (H-score)			—			<0.001			0.031
Mean (SD)	—	—		12.7 (31.6)	28.6 (39.9)		24.9 (38.6)	16.5 (34.5)	
RhoA (%)			<0.001			—			0.185
Mean (SD)	26.2 (28)	46.9 (28.3)		—	—		34.1 (30.6)	38.3 (29.2)	
Claudin 18 (%)			0.113			0.989			0.185
Mean (SD)	37.5 (29.9)	32.4 (29.8)		35.1 (30.5)	35.0 (29.4)		34.1 (30.6)	38.3 (29.2)	
Postoperative complication (POC)			0.693			0.462			0.602
No									
POC/Clavien I-II	155 (86.1)	143 (84.6)		151 (86.8)	147 (84)		146 (84.4)	152 (86.4)	
Clavien III-V	25 (13.9)	26 (15.4)		23 (13.2)	28 (16)		27 (15.6)	24 (13.6)	
Chemotherapy (all)			0.382			0.119			0.231
No	80 (44.4)	83 (49.1)		74 (42.5)	89 (50.9)		75 (43.4)	88 (50)	
Yes	100 (55.6)	86 (50.9)		100 (57.5)	86 (49.1)		98 (56.6)	88 (50)	
Disease recurrence			na			na			na
No	114 (63.3)	130 (79.9)		110 (63.2)	134 (76.6)		123 (71.1)	121 (68.8)	
Yes	66 (36.7)	39 (23.1)		64 (36.8)	41 (23.4)		50 (28.9)	55 (31.2)	
Death			na			na			na
No	91 (50.6)	101 (59.8)		94 (54)	98 (56)		93 (53.8)	99 (56.2)	
Yes	89 (49.4)	68 (40.2)		80 (46)	77 (44)		80 (46.2)	77 (43.8)	

BMI, body mass index; SD, standard deviation. *p*-values in bold are statistically significant.

Supplementary Table S2. Pearson correlation test for IHC markers

		c-MET	RhoA	CLDN18
c-MET	Pearson Correlation coefficient (r)	—	0.250	– 0.139
	<i>p</i> -value	—	<0.001	0.010
RhoA	Pearson Correlation coefficient (r)	0.250	—	0.023
	<i>p</i> -value	<0.001	—	0.664
CLDN18	Pearson Correlation coefficient (r)	– 0.139	0.023	—
	<i>p</i> -value	0.010	0.664	—
HER2	Pearson Correlation coefficient (r)	0.160	0.049	– 0.107
	<i>p</i> -value	0.002	0.376	0.052
E-cadherin	Pearson Correlation coefficient (r)	– 0.122	– 0.125	0.025
	<i>p</i> -value	0.028	0.024	0.657